FI962591A0 - Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä - Google Patents
Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitäInfo
- Publication number
- FI962591A0 FI962591A0 FI962591A FI962591A FI962591A0 FI 962591 A0 FI962591 A0 FI 962591A0 FI 962591 A FI962591 A FI 962591A FI 962591 A FI962591 A FI 962591A FI 962591 A0 FI962591 A0 FI 962591A0
- Authority
- FI
- Finland
- Prior art keywords
- growth hormone
- pct
- hormone releasing
- compounds
- date jun
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK143893A DK143893D0 (ja) | 1993-12-23 | 1993-12-23 | |
| DK7594 | 1994-01-17 | ||
| DK78194 | 1994-06-30 | ||
| DK116594 | 1994-10-07 | ||
| PCT/DK1994/000486 WO1995017422A1 (en) | 1993-12-23 | 1994-12-22 | Compounds with growth hormone releasing properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI962591A0 true FI962591A0 (fi) | 1996-06-20 |
| FI962591A FI962591A (fi) | 1996-06-20 |
Family
ID=27439242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI962591A FI962591A (fi) | 1993-12-23 | 1996-06-20 | Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5854211A (ja) |
| EP (1) | EP0736038B1 (ja) |
| JP (1) | JP3759748B2 (ja) |
| CN (1) | CN1052730C (ja) |
| AT (1) | ATE202785T1 (ja) |
| AU (1) | AU683121B2 (ja) |
| CA (1) | CA2179598A1 (ja) |
| CZ (1) | CZ291382B6 (ja) |
| DE (1) | DE69427650T2 (ja) |
| FI (1) | FI962591A (ja) |
| HU (1) | HU221092B1 (ja) |
| IL (1) | IL112111A (ja) |
| NO (1) | NO315611B1 (ja) |
| PL (1) | PL181286B1 (ja) |
| RU (1) | RU2167881C2 (ja) |
| TW (1) | TW438810B (ja) |
| UA (1) | UA45962C2 (ja) |
| WO (1) | WO1995017422A1 (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2176140A1 (en) * | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
| US6531314B1 (en) | 1996-12-10 | 2003-03-11 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
| ATE334394T1 (de) | 1995-12-13 | 2006-08-15 | Merck & Co Inc | Testverfahren für die sekretionsrezeptoren von wachstumshormonen |
| GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
| US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| EP1005484A1 (en) | 1997-06-20 | 2000-06-07 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| JP4382279B2 (ja) | 1998-01-16 | 2009-12-09 | サファイア セラピューティクス，インコーポレイティド | 成長ホルモン放出特性を有する化合物 |
| US6682908B1 (en) | 1998-07-10 | 2004-01-27 | Merck & Co., Inc. | Mouse growth hormone secretagogue receptor |
| EP1097170A1 (en) | 1998-07-13 | 2001-05-09 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
| CA2340095A1 (en) | 1998-08-10 | 2000-02-24 | Merck & Co., Inc. | Canine growth hormone secretagogue receptor |
| PT1141014E (pt) | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
| AU759022B2 (en) | 1999-02-18 | 2003-04-03 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| AU5630800A (en) * | 1999-06-22 | 2001-01-09 | Arno F Spatola | Antimicrobial agents |
| EP1204321B1 (en) * | 1999-07-26 | 2005-11-09 | Baylor College Of Medicine | Super-active porcine growth hormone releasing hormone analog |
| CA2401749A1 (en) * | 2000-03-23 | 2001-09-27 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| EP1282437B1 (en) | 2000-05-16 | 2008-03-19 | Genentech, Inc. | Treatment of cartilage disorders |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| DK2274978T3 (en) | 2003-09-12 | 2015-06-15 | Ipsen Biopharmaceuticals Inc | Methods of treating an insulin-like growth factor-I (IGF-I) deficiency |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| JP2010518090A (ja) | 2007-02-09 | 2010-05-27 | トランザイム・ファーマ，インコーポレイテッド | 大環状グレリン受容体修飾因子およびその使用方法 |
| US20100099640A1 (en) | 2007-05-04 | 2010-04-22 | Joannes Geuns | Tissue degeneration protection |
| WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| JPWO2016129645A1 (ja) | 2015-02-10 | 2017-10-26 | 富士フイルム株式会社 | 光学部材、光学素子、液晶表示装置および近接眼光学部材 |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803261A (en) * | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
| US5480869A (en) * | 1990-01-09 | 1996-01-02 | The Regents Of The University Of California | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues |
| IL98910A0 (en) * | 1990-07-24 | 1992-07-15 | Polygen Holding Corp | Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them |
| US5486505A (en) * | 1990-07-24 | 1996-01-23 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
| US5663146A (en) * | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| US5470753A (en) * | 1992-09-03 | 1995-11-28 | Selectide Corporation | Peptide sequencing using mass spectrometry |
| SE9300012D0 (sv) * | 1993-01-05 | 1993-01-05 | Astra Ab | New peptides |
| US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| WO1995017423A1 (en) * | 1993-12-23 | 1995-06-29 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
-
1994
- 1994-12-22 US US08/464,679 patent/US5854211A/en not_active Expired - Fee Related
- 1994-12-22 RU RU96115195/04A patent/RU2167881C2/ru not_active IP Right Cessation
- 1994-12-22 JP JP51711095A patent/JP3759748B2/ja not_active Expired - Fee Related
- 1994-12-22 EP EP95904405A patent/EP0736038B1/en not_active Expired - Lifetime
- 1994-12-22 IL IL11211194A patent/IL112111A/xx not_active IP Right Cessation
- 1994-12-22 CZ CZ19961833A patent/CZ291382B6/cs not_active IP Right Cessation
- 1994-12-22 UA UA96062484A patent/UA45962C2/uk unknown
- 1994-12-22 AT AT95904405T patent/ATE202785T1/de active
- 1994-12-22 CN CN94194588A patent/CN1052730C/zh not_active Expired - Fee Related
- 1994-12-22 WO PCT/DK1994/000486 patent/WO1995017422A1/en active IP Right Grant
- 1994-12-22 CA CA002179598A patent/CA2179598A1/en not_active Abandoned
- 1994-12-22 PL PL94315114A patent/PL181286B1/pl not_active IP Right Cessation
- 1994-12-22 DE DE69427650T patent/DE69427650T2/de not_active Expired - Fee Related
- 1994-12-22 HU HU9601740A patent/HU221092B1/hu not_active IP Right Cessation
- 1994-12-22 AU AU13106/95A patent/AU683121B2/en not_active Ceased
-
1995
- 1995-01-13 TW TW084100272A patent/TW438810B/zh active
-
1996
- 1996-06-20 FI FI962591A patent/FI962591A/fi not_active IP Right Cessation
- 1996-06-21 NO NO19962664A patent/NO315611B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU683121B2 (en) | 1997-10-30 |
| CA2179598A1 (en) | 1995-06-29 |
| PL315114A1 (en) | 1996-10-14 |
| NO315611B1 (no) | 2003-09-29 |
| IL112111A (en) | 2000-07-16 |
| CZ183396A3 (en) | 1997-02-12 |
| CN1138334A (zh) | 1996-12-18 |
| EP0736038B1 (en) | 2001-07-04 |
| HUT74820A (en) | 1997-02-28 |
| CZ291382B6 (cs) | 2003-02-12 |
| AU1310695A (en) | 1995-07-10 |
| US5854211A (en) | 1998-12-29 |
| TW438810B (en) | 2001-06-07 |
| JP3759748B2 (ja) | 2006-03-29 |
| UA45962C2 (uk) | 2002-05-15 |
| NO962664L (no) | 1996-08-23 |
| NO962664D0 (no) | 1996-06-21 |
| FI962591A (fi) | 1996-06-20 |
| WO1995017422A1 (en) | 1995-06-29 |
| DE69427650T2 (de) | 2001-11-22 |
| ATE202785T1 (de) | 2001-07-15 |
| HU221092B1 (en) | 2002-08-28 |
| IL112111A0 (en) | 1995-03-15 |
| CN1052730C (zh) | 2000-05-24 |
| RU2167881C2 (ru) | 2001-05-27 |
| EP0736038A1 (en) | 1996-10-09 |
| PL181286B1 (pl) | 2001-07-31 |
| HU9601740D0 (en) | 1996-08-28 |
| JPH09506873A (ja) | 1997-07-08 |
| DE69427650D1 (de) | 2001-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO962664D0 (no) | Forbindelser med veksthormonfrigjörende egenskaper | |
| DE69327536D1 (de) | Fibrinogenrezeptor-antagonisten | |
| PT804252E (pt) | Agentes queladores metalicos que contem monoaminas diamidas e tiois | |
| DE69507029D1 (de) | Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten | |
| ATE185548T1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
| FI964332A (fi) | Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen | |
| ATE211384T1 (de) | Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera | |
| DK1077941T3 (da) | Forbindelser med væksthormonfrigörende egenskaber | |
| IL126235A (en) | Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use | |
| NO20010940L (no) | TAN-1057 derivater | |
| MX9604762A (es) | Nuevas sulfonamidas y procedimiento para su preparacion. | |
| DE60035133D1 (de) | Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten | |
| DK1100824T3 (da) | Forbindelser med væksthormonfrigivende egenskaber | |
| ATE243521T1 (de) | Verwendung von biopolymeren zur behandlung der muskeln | |
| NO20012169L (no) | Forbindelser med veksthormonfrigjörende egenskaper | |
| ATE224716T1 (de) | Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid | |
| DE69503635D1 (de) | Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen | |
| TH32887A (th) | สารประกอบทางเคมี |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |